Development And Characterization Of Niosomal Transdermal Formulation Loaded Lecarnidipine Hydrochloride

Introduction and Background: For several medications, matrix-based transdermal formulations have been created. Derma as a delivery system for medicinal agents has recently seen a renaissance as a viable option for both local and systemic drug delivery. The current work set out to design and evaluate transdermal medication delivery patches based on niosomes as its aim and objectives. Material and Methods: An improved formulation of LCP nanoparticles with a polydispersity index and a particle size of 225 nm was achieved using solvent evaporation. Using solvent casting techniques, LCP patches were prepared by dispersing nanoparticles in a variety of polymers and sodium alginate concentrations. The patches were then optimized using a central composite design. In-vitro drug release studies and ex-vivo skin permeation studies were conducted. Results: A member of the BCS class of drugs, lecarnidipine hydrochloride has a poor solubility but, because to its niosomes, is able to pass the blood-brain barrier and enter the bloodstream. The transdermal patch now contains lecarnidipine niosomes, which were successfully integrated utilizing HPMC E5 and HPMC 15cps. A lecarnidipine niosomal patch with a 10 mg dosage released its contents more quickly.